 - Patients must be prior recipients of allogeneic BMT matched 66 or 56 according to the National Marrow Donor Program for any hematologic malignancy. Eligible patients would include those with leukemia, non Hodgkins Lymphoma, Hodgkins Disease, myelodysplastic syndrome and multiple myeloma. 